Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19785996 | 0.90 | CD274 (0.49) | CD274PDCD1 | |
| SCHEMBL19785504 | 0.87 | PDCD1 (0.41) | CD274PDCD1CDK4CCND1TTK | |
| SCHEMBL29893975 | 0.85 | CD274 (0.51) | CD274PDCD1ABL1EGFRSRC | |
| SCHEMBL19779553 | 0.85 | CD274 (0.51) | CD274PDCD1ABL1EGFRSRC | |
| SCHEMBL19785820 | 0.82 | PDCD1 (0.68) | CD274PDCD1 | |
| SCHEMBL19785768 | 0.82 | PDCD1 (0.43) | CD274PDCD1 | |
| SCHEMBL19785839 | 0.79 | PDCD1 (0.66) | CD274PDCD1 | |
| SCHEMBL19785493 | 0.77 | PDCD1 (0.52) | CD274PDCD1 | |
| SCHEMBL19785961 | 0.75 | CD274 (0.51) | CD274PDCD1 | |
| SCHEMBL19780011 | 0.74 | CD274 (0.54) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018013789-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-01-18 | — | — | WO | disclosed |